Bora Pharmaceuticals
Bora Pharmaceuticals, headquartered in California, is a prominent player in the pharmaceutical industry, specialising in contract development and manufacturing services. Founded in 2010, the company has rapidly expanded its operational footprint, with significant facilities in North America and Asia, catering to a global clientele. Bora Pharmaceuticals is renowned for its expertise in the development and production of complex dosage forms, including solid oral, semi-solid, and liquid formulations. Their commitment to quality and innovation has positioned them as a trusted partner for pharmaceutical companies seeking reliable manufacturing solutions. With a focus on enhancing patient outcomes, Bora Pharmaceuticals has achieved notable milestones, including successful collaborations with leading pharmaceutical firms. Their dedication to excellence and customer satisfaction continues to solidify their reputation in the competitive landscape of pharmaceutical manufacturing.
DitchCarbon Score
How does Bora Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bora Pharmaceuticals's score of 15 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bora Pharmaceuticals's reported carbon emissions
In 2023, Bora Pharmaceuticals reported total carbon emissions of approximately 43,145,108.1 kg CO2e, a significant increase from about 31,207,569.8 kg CO2e in 2022. The emissions breakdown for 2023 includes Scope 1 emissions of about 28,945,040.1 kg CO2e and Scope 2 emissions of approximately 14,200,068.0 kg CO2e. Notably, the company has not disclosed any Scope 3 emissions data for 2023. Despite the increase in total emissions, Bora Pharmaceuticals has not set specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction strategies suggests a need for further development in their sustainability efforts. As the pharmaceutical industry increasingly prioritises climate action, Bora's commitment to addressing its carbon footprint will be crucial for aligning with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 20,713,099.8 | 00,000,000.0 |
| Scope 2 | 10,494,470 | 00,000,000 |
| Scope 3 | 21,525,110.2 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bora Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
